Payload Information

General Information of This Payload
Payload ID
PAY0JJJPM
Name
Topoisomerase I inhibitor
Synonyms
Topoisomerase I inhibitor
   Click to Show/Hide
Target(s) DNA topoisomerase 1 (TOP1)
 Target Info 
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
MHB036C [Phase 1/2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05642949  Phase Status Phase 1/2
Clinical Description
Phase 1/2, multi-center, open-label, dose escalation and cohort expansion study to evaluate the safety/tolerability, pharmacokinetics and efficacy of MHB036C in participants with advanced or metastatic solid tumors.
AZD-8205 [Phase 1/2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Patients 18 years old with cholangiocarcinoma, breast, ovarian or endometrial cancers and ECOG PS 0-1.
Related Clinical Trial
NCT Number NCT05123482  Phase Status Phase 1/2
Clinical Description
A phase 1/2a multi-center, open-label master protocol to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of AZD8205 in participants with advanced or metastatic solid malignancies.
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [4]
Efficacy Data Objective Response Rate (ORR)
69.00%
Positive VTCN1 expression (VTCN1+++/++)
Method Description
In the study of 26 PDX tumors,single administration of 3.5 mg/kg AZD8205 to determine the ORR,according to modified RECIST criteria,which correlated with homologous recombination repair (HRR) deficiency (HRD) and elevated levels of B7-H4 in HRR-proficient models.
In Vivo Model Multiple tumor PDX model
FDA-022 [Phase 1/2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT05564858  Phase Status Phase 1
Clinical Description
A phase study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA022-BB05 in subjects with advanced solid malignant tumors.
TQB2102 [Phase 1]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Related Clinical Trial
NCT Number NCT05735496  Phase Status Phase 1
Clinical Description
A phase 1 study of TQB2102 injection in patients with advanced cancers.
References
Ref 1 Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors, NCT05642949
Ref 2 First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521. Cancer Res (2023) 83 (8_Supplement): CT185.
Ref 3 A PhaseStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors, NCT05564858
Ref 4 Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clin Cancer Res. 2023 Mar 14;29(6):1086-1101.
Ref 5 A Phase I Study of TQB2102 Injection in Patients With Advanced Cancers

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.